Altimmune's Shares Surge After FDA Breakthrough Designation for Pemvidutide
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jan 05 2026
0mins
Should l Buy ALT?
Altimmune Inc's shares rose by 19.94% in pre-market trading, reaching a 5-day high, as the company announced significant news regarding its drug pemvidutide.
The surge is attributed to Altimmune receiving FDA Breakthrough Therapy Designation for pemvidutide, based on promising Phase 2b trial results that demonstrated significant improvements in treating metabolic dysfunction-associated steatohepatitis (MASH). This designation is expected to enhance the company's market position and drive future growth, reflecting strong investor optimism.
This breakthrough not only positions Altimmune favorably in the biopharmaceutical sector but also indicates a commitment to addressing critical patient needs, potentially leading to long-term value creation for shareholders.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy ALT?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on ALT
Wall Street analysts forecast ALT stock price to rise
4 Analyst Rating
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.460
Low
12.00
Averages
16.00
High
20.00
Current: 4.460
Low
12.00
Averages
16.00
High
20.00
About ALT
Altimmune, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on developing next-generation peptide-based therapeutics. It is developing pemvidutide, a GLP-1/glucagon dual receptor agonist for the treatment of obesity, metabolic dysfunction-associated steatohepatitis (MASH) and other indications. Activation of the GLP-1 and glucagon receptors is believed to mimic the complementary effects of diet and exercise on weight loss, with GLP-1 suppressing appetite and glucagon increasing energy expenditure. Glucagon is also recognized as having direct effects on hepatic fat metabolism, to rapid reductions in levels of liver fat and serum lipids. The Company has completed the MOMENTUM Phase II obesity trial and is being studied in the IMPACT Phase IIb MASH trial. The Company also develops and commercializes surfactant-functionalized (EuPort domain) incretin-based peptide therapeutics, including (GLP-1-glucagon)/oxyntomodulin, and variants.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Altimmune Receives Buy Rating from Analysts Amid Promising Drug Trials
- Analyst Support: On February 13, Titan Partners initiated coverage of Altimmune (NASDAQ:ALT) with a Buy rating and a $7 target, highlighting promising Phase II results for pemvidutide, suggesting potential for stock price appreciation if Phase III data is strong.
- Successful Financing: On January 29, Altimmune closed a direct offering of 17.05 million shares, generating $75 million in gross proceeds, with plans to use net proceeds to fund the upcoming Phase 3 trial of pemvidutide, thereby enhancing financial flexibility.
- FDA Designation: Pemvidutide has received Breakthrough Therapy Designation from the FDA for treating metabolic dysfunction-associated steatohepatitis (MASH), indicating its potential in addressing obesity and liver diseases, which boosts investor confidence.
- Long-Term Outlook: Despite Evercore ISI lowering Altimmune's price target from $25 to $22, the firm reiterated its Outperform rating, reflecting optimism about pemvidutide's long-term prospects and the rationale behind its therapeutic approach.
See More
Altimmune Closes Direct Offering of 17 Million Shares Raising $75 Million
- Funding Size: Altimmune successfully closed a registered direct offering of 17,045,454 shares, raising approximately $75 million, which will support the upcoming Phase 3 trial for pemvidutide.
- Trial Preparation: The proceeds will be allocated towards the initiation of the Phase 3 clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), aimed at validating the efficacy of pemvidutide and enhancing the company's market competitiveness in liver disease treatment.
- Strategic Flexibility: CEO Jerry Durso emphasized that this financing strengthens Altimmune's balance sheet and increases operational and strategic flexibility, ensuring the company can continue delivering meaningful impacts for patients and long-term value for shareholders.
- Market Response: The pre-funded warrants in the offering have an exercise price of $0.001 per share, are exercisable immediately, and have no expiration date, reflecting investor confidence in Altimmune's future developments, which may positively influence the company's stock price.
See More
Longevity Infrastructure Market Undergoes Structural Reset
- Market Size Surge: The global longevity infrastructure is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Growth: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are set to accelerate to $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell encapsulation technology and precision metabolic delivery.
- Technological Innovation Breakthrough: Avant Technologies' Cell-in-a-Box® technology addresses the critical issue of transplanted cells being destroyed by the immune system by creating a protective barrier around them, thus eliminating the need for immunosuppressive drugs and enhancing the safety and scalability of diabetes therapies.
- Massive Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SG Austria to develop a bioartificial pancreas aims to restore natural glucose control and meet the demands of this vast market.
See More
Global Capital Shifts to Longevity Infrastructure Valued at $27 Trillion
- Market Growth Surge: The global longevity infrastructure market is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Expansion: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are accelerating towards $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell-encapsulation technology and precision metabolic delivery.
- Innovative Technology Application: Avant Technologies showcased its Cell-in-a-Box® technology at the EPITA Symposium, aimed at addressing the issue of transplanted cells being destroyed by the immune system, providing a safe and scalable diabetes treatment solution that could significantly enhance the quality of life for type 1 and insulin-dependent type 2 diabetes patients.
- Significant Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SGAustri to develop a bioartificial pancreas is poised to capture a significant share of this vast market.
See More
Altimmune Announces $75 Million Stock Offering Amid Market Volatility
- Stock Offering Impact: Altimmune's announcement of a direct offering of 17,045,454 shares at approximately $4.40 each is expected to generate about $75 million in gross proceeds, yet this has led to a 17.15% drop in stock price, indicating market concerns over its funding strategy.
- Clear Use of Funds: The proceeds from this offering will be allocated to preparations for the upcoming Phase 3 trial for MASH (metabolic dysfunction-associated steatohepatitis) and general working capital, highlighting the company's commitment to advancing its drug development.
- Market Performance Analysis: Despite a 26.33% decline in share price over the past year, Altimmune's stock remains above its 20-day and 100-day simple moving averages, suggesting short-term strength; however, the RSI indicates overbought conditions, signaling potential correction risks ahead.
- Product Development Outlook: Altimmune is developing pemvidutide as a potential treatment for obesity and metabolic-associated steatohepatitis, and the success of this funding will significantly impact its future market performance and growth trajectory.
See More
Qorvo Shares Drop After Disappointing Earnings Guidance
- Disappointing Earnings: Qorvo reported third-quarter financial results with fourth-quarter revenue guidance projected between $775 million and $825 million, significantly below the market estimate of $904.59 million, indicating sales pressure on the company.
- Lowered Earnings Expectations: The company anticipates adjusted earnings per share in the range of $1.05 to $1.35 for the fourth quarter, compared to the market expectation of $1.37, reflecting potential declines in profitability.
- Significant Stock Reaction: In pre-market trading, Qorvo shares fell 10.5% to $74.11, as investor concerns over the financial outlook weakened market confidence.
- Market Trend Divergence: While Nasdaq 100 futures rose over 200 points, Qorvo's negative earnings report impacted its stock price, highlighting a divergence between individual stock performance and overall market trends.
See More
Altimmune Receives Buy Rating from Analysts Amid Promising Drug Trials
- Analyst Support: On February 13, Titan Partners initiated coverage of Altimmune (NASDAQ:ALT) with a Buy rating and a $7 target, highlighting promising Phase II results for pemvidutide, suggesting potential for stock price appreciation if Phase III data is strong.
- Successful Financing: On January 29, Altimmune closed a direct offering of 17.05 million shares, generating $75 million in gross proceeds, with plans to use net proceeds to fund the upcoming Phase 3 trial of pemvidutide, thereby enhancing financial flexibility.
- FDA Designation: Pemvidutide has received Breakthrough Therapy Designation from the FDA for treating metabolic dysfunction-associated steatohepatitis (MASH), indicating its potential in addressing obesity and liver diseases, which boosts investor confidence.
- Long-Term Outlook: Despite Evercore ISI lowering Altimmune's price target from $25 to $22, the firm reiterated its Outperform rating, reflecting optimism about pemvidutide's long-term prospects and the rationale behind its therapeutic approach.
See More
Altimmune Closes Direct Offering of 17 Million Shares Raising $75 Million
- Funding Size: Altimmune successfully closed a registered direct offering of 17,045,454 shares, raising approximately $75 million, which will support the upcoming Phase 3 trial for pemvidutide.
- Trial Preparation: The proceeds will be allocated towards the initiation of the Phase 3 clinical trial for metabolic dysfunction-associated steatohepatitis (MASH), aimed at validating the efficacy of pemvidutide and enhancing the company's market competitiveness in liver disease treatment.
- Strategic Flexibility: CEO Jerry Durso emphasized that this financing strengthens Altimmune's balance sheet and increases operational and strategic flexibility, ensuring the company can continue delivering meaningful impacts for patients and long-term value for shareholders.
- Market Response: The pre-funded warrants in the offering have an exercise price of $0.001 per share, are exercisable immediately, and have no expiration date, reflecting investor confidence in Altimmune's future developments, which may positively influence the company's stock price.
See More
Longevity Infrastructure Market Undergoes Structural Reset
- Market Size Surge: The global longevity infrastructure is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Growth: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are set to accelerate to $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell encapsulation technology and precision metabolic delivery.
- Technological Innovation Breakthrough: Avant Technologies' Cell-in-a-Box® technology addresses the critical issue of transplanted cells being destroyed by the immune system by creating a protective barrier around them, thus eliminating the need for immunosuppressive drugs and enhancing the safety and scalability of diabetes therapies.
- Massive Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SG Austria to develop a bioartificial pancreas aims to restore natural glucose control and meet the demands of this vast market.
See More
Global Capital Shifts to Longevity Infrastructure Valued at $27 Trillion
- Market Growth Surge: The global longevity infrastructure market is projected to reach $27 trillion by 2030, driving a shift in the healthcare sector towards regenerative medicine, which is expected to grow to $578.59 billion by 2033, indicating substantial investment potential.
- Cell Therapy Market Expansion: The cell therapy market is anticipated to hit $8.85 billion by 2026, while AI-driven drug discovery platforms are accelerating towards $24.51 billion, suggesting that institutional investors are positioning for the convergence of cell-encapsulation technology and precision metabolic delivery.
- Innovative Technology Application: Avant Technologies showcased its Cell-in-a-Box® technology at the EPITA Symposium, aimed at addressing the issue of transplanted cells being destroyed by the immune system, providing a safe and scalable diabetes treatment solution that could significantly enhance the quality of life for type 1 and insulin-dependent type 2 diabetes patients.
- Significant Market Opportunity: With 589 million people globally living with type 1 and insulin-dependent type 2 diabetes, projected to rise to 853 million by 2050, Avant's partnership with SGAustri to develop a bioartificial pancreas is poised to capture a significant share of this vast market.
See More
Altimmune Announces $75 Million Stock Offering Amid Market Volatility
- Stock Offering Impact: Altimmune's announcement of a direct offering of 17,045,454 shares at approximately $4.40 each is expected to generate about $75 million in gross proceeds, yet this has led to a 17.15% drop in stock price, indicating market concerns over its funding strategy.
- Clear Use of Funds: The proceeds from this offering will be allocated to preparations for the upcoming Phase 3 trial for MASH (metabolic dysfunction-associated steatohepatitis) and general working capital, highlighting the company's commitment to advancing its drug development.
- Market Performance Analysis: Despite a 26.33% decline in share price over the past year, Altimmune's stock remains above its 20-day and 100-day simple moving averages, suggesting short-term strength; however, the RSI indicates overbought conditions, signaling potential correction risks ahead.
- Product Development Outlook: Altimmune is developing pemvidutide as a potential treatment for obesity and metabolic-associated steatohepatitis, and the success of this funding will significantly impact its future market performance and growth trajectory.
See More
Qorvo Shares Drop After Disappointing Earnings Guidance
- Disappointing Earnings: Qorvo reported third-quarter financial results with fourth-quarter revenue guidance projected between $775 million and $825 million, significantly below the market estimate of $904.59 million, indicating sales pressure on the company.
- Lowered Earnings Expectations: The company anticipates adjusted earnings per share in the range of $1.05 to $1.35 for the fourth quarter, compared to the market expectation of $1.37, reflecting potential declines in profitability.
- Significant Stock Reaction: In pre-market trading, Qorvo shares fell 10.5% to $74.11, as investor concerns over the financial outlook weakened market confidence.
- Market Trend Divergence: While Nasdaq 100 futures rose over 200 points, Qorvo's negative earnings report impacted its stock price, highlighting a divergence between individual stock performance and overall market trends.
See More
